drugset / Trial / NCT04361253
Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy
RandomizedParallel-groupDouble-blindTreatment
Summary
In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS.
Timeline
- Start
- 2020-04-30
- Primary completion
- 2021-04-01
- Completion
- 2021-06-30
Outcome
Outcome not reported
Stopped: “Futility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | High-Titer COVID-19 Convalescent Plasma | Protein / enzyme biologic | 250 ml | — |